Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study

被引：28
|
作者：
Mukherjee, Sarbajit [1 ]
Ibrahimi, Sami [1 ]
Khalid, Bilal [1 ]
Roman, Darwin [2 ]
Zhao, Daniel [3 ]
Aljumaily, Raid [1 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Hematol Oncol, Oklahoma City, OK USA
[2] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2019年 / 25卷 / 03期
关键词：
D O I：
10.1177/1078155218771152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [1] Efficacy of PD-1/PD-L1 therapy: Do proton pump inhibitors affect the outcome?
    Mukherjee, Sarbajit
    Khalid, Bilal
    Ibrahimi, Sami
    Morton, Jordan Malie
    Roman, Darwin
    Zhao, Yan D.
    Aljumaily, Raid
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [2] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [3] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [4] Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
    Liu, Junjie
    Tao, Haisu
    Yuan, Tong
    Li, Jiang
    Li, Jian
    Liang, Huifang
    Huang, Zhiyong
    Zhang, Erlei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy
    Yamaguchi, Hirohito
    Wang, Shao-Chun
    Hung, Mien-Chie
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [6] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [7] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Mengke Niu
    Ming Yi
    Ning Li
    Suxia Luo
    Kongming Wu
    Experimental Hematology & Oncology, 10
  • [8] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    CANCERS, 2022, 14 (20)
  • [9] Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
    Zhang, Yiru
    Yao, Qigu
    Pan, Yong
    Fang, Xinru
    Xu, Haoying
    Zhao, Tingxiao
    Zhu, Guangqi
    Jiang, Tianan
    Li, Shibo
    Cao, Hongcui
    CANCERS, 2023, 15 (03)
  • [10] Impact of PD-L1 feedback modulation on the sensitivity of anti-PD-1/PD-L1
    Zhu, Jian
    Zhu, Rebecca L.
    CANCER RESEARCH, 2019, 79 (13)
12345